[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349389-105":59,"doc-detail-349389-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","sdc1-knockdown-suppresses-malignant-phenotypes-of-breast-cancer-research-article-mapk-signaling-pathway","SDC1 Knockdown Suppresses Malignant Phenotypes of Breast Cancer - Research Article - MAPK Signaling Pathway","","Breast cancer remains a major cause of morbidity and mortality worldwide, making molecular mechanism research essential for improved prognosis and treatment. This study analyzes heparan sulfate proteoglycan Syndecan-1 (SDC1) in breast cancer progression and downstream signaling. Bioinformatics from GEO and TCGA shows higher SDC1 expression in tumors, linked to advanced stage, lymph node metastasis, and poor survival. RT-qPCR and Western blot confirm overexpression. Lentiviral SDC1 knockdown reduces proliferation, migration, and angiogenesis; MAPK pathway phosphorylation and rescue by C16-PAF support an MAPK-dependent mechanism. Xenografts show reduced growth and microvessel density, partially reversed by C16-PAF, positioning SDC1 as a biomarker and therapeutic target.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sdc1-knockdown-suppresses-malignant-phenotypes-of-breast-cancer-research-article-mapk-signaling-pathway/349389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sdc1-knockdown-suppresses-malignant-phenotypes-of-breast-cancer-research-article-mapk-signaling-pathway/349389.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What evidence supports the findings in vivo?","Question",{"text":112,"@type":113},"In vivo xenograft models confirm that SDC1 knockdown reduces tumor growth and microvessel density, with partial reversal upon C16-PAF treatment.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},349389,1790216453,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>SDC1 Knockdown Suppresses Malignant Phenotypes of\u003Cbr>Breast Cancer by Modulating the MAPK Signaling Pathway\u003Cbr>Weixun Lin1,2  | Xiuying Chen3 | Juan Zou2 | Yanxian Chen2 | Zeqi Ji2 | Zhiyang Li2  | Bo Xu1\u003Cbr>1Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China | 2Department of Thyroid, Breast and Hernia Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China | 3Department of Ophthalmology, People's Hospital of Chenghai Shantou, Shantou, Guangdong, China\u003Cbr>Correspondence: Zhiyang Li ([s_zyli4@stu.edu.cn](s_zyli4@stu.edu.cn)) | Bo Xu ([aabb97@163.com](aabb97@163.com))\u003Cbr>Received: 20 November 2025 | Revised: 5 May 2026 | Accepted: 27 May 2026\u003Cbr>Keywords: breast cancer | malignant phenotypes | MAPK signaling pathway | prognostic markers | SDC1 |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Breast cancer remains a leading cause of morbidity and mortality among women worldwide, necessitating in-depth research into its molecular mechanisms to improve prognosis and treatment strategies. This study investigates the expression profile and functional role of heparan sulfate proteoglycan Syndecan-1 (SDC1) in breast cancer progression, with a focus on its downstream signaling pathways. Utilizing bioinformatics analysis of datasets from the GEO and TCGA databases, we identified significantly elevated SDC1 expression in breast cancer tissues compared to normal counterparts, correlating with advanced tumor stage, lymph node metastasis, and poor survival outcomes. Clinical sample validation through RT-qPCR and Western blot confirmed SDC1 overexpression in breast cancer tissues and cell lines. Functional experiments, including SDC1 knockdown via lentiviral infection, revealed that reduced SDC1 expression markedly impairs breast cancer cell proliferation, migration, and angiogenesis, as evidenced by CCK-8, EdU, wound healing, Transwell, and tube formation assays. Mechanistically, transcriptome sequencing and Western blot analysis demonstrated that SDC1 knockdown significantly suppressed the phosphorylation of key MAPK pathway components (ERK1/2, JNK, and p38) . Rescue experiments using the MAPK agonist C16-PAF effectively reversed the inhibitory effects ofSDC1 knockdown on cell proliferation, migration, and angiogenesis. Furthermore, in vivo xenograft models confirmed that SDC1 knockdown suppressed tumor growth and reduced microvessel density, while C16-PAF treatment partially reversed these effects. Collectively, our findings demonstrate that SDC1 promotes breast cancer progression by activating the MAPK signaling pathway, highlighting SDC1 as a potential prognostic biomarker and therapeutic target in breast cancer. |  |\n| 1 | Introduction | This may be attributed to the dynamic adaptations that tumors acquire through metabolic reprogramming and interactions |\n| Breast cancer stands as one of the most prevalent malignant tu- | with the microenvironment during their progression [6, 7] . As |\n| mors among women worldwide, characterized by high morbid- | tumors evolve from precancerous lesions to localized lesions |\n| ity and mortality rates, posing a severe threat to female health | and ultimately progress to metastatic cancer, the metabolic |\n| [1–3] . Despite significant advancements in molecular subtyping | characteristics of tumor cells and their dependency on the tumor |\n| and targeted therapies that have markedly improved the sur- | microenvironment undergo alterations throughout the cancer |\n| vival outcomes for some patients, numerous individuals still | progression process [7, 8]. Encompassing aberrant cell prolifera- |\n| encounter challenges such as drug resistance, recurrence, or | tion, migration, invasion, and angiogenesis. These changes pose |\n| distant metastasis, leading to unsatisfactory prognoses [4, 5] . | challenges to the selection of treatment strategies a","cbCaiogwP6j6sZdR","https://ap.wps.com/l/cbCaiogwP6j6sZdR","pdf",8886569,18,"English","# Introduction\n## Breast cancer background and treatment challenges\n## SDC1 and its roles in cancer progression\n# Materials and Methods","[{\"question\":\"What evidence supports the findings in vivo?\",\"answer\":\"In vivo xenograft models confirm that SDC1 knockdown reduces tumor growth and microvessel density, with partial reversal upon C16-PAF treatment.\"}]","SDC1 Knockdown Suppresses Malignant Phenotypes of Breast Cancer - Research Article - MAPK Signaling Pathway | PDF",1790083112,45,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e88df58619c36163fca10d04c446f95e.webp",983,1291,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17effc822a121cc9d9145bdfcf029ecc.webp",982,1290,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89f6e3b108b33f85d964ddf48725cca7.webp",981,1289,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3992adbe36a113a001d3f5834f94e4f3.webp",980,1287]